PE20231656A1 - Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos - Google Patents

Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos

Info

Publication number
PE20231656A1
PE20231656A1 PE2023001523A PE2023001523A PE20231656A1 PE 20231656 A1 PE20231656 A1 PE 20231656A1 PE 2023001523 A PE2023001523 A PE 2023001523A PE 2023001523 A PE2023001523 A PE 2023001523A PE 20231656 A1 PE20231656 A1 PE 20231656A1
Authority
PE
Peru
Prior art keywords
crystalline forms
deoxycytidine kinase
kinase inhibitor
dck
methods
Prior art date
Application number
PE2023001523A
Other languages
English (en)
Spanish (es)
Inventor
David Litzinger
Kenneth A Schultz
Original Assignee
Trethera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trethera Corp filed Critical Trethera Corp
Publication of PE20231656A1 publication Critical patent/PE20231656A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2023001523A 2020-11-02 2021-11-01 Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos PE20231656A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108803P 2020-11-02 2020-11-02
US202163190107P 2021-05-18 2021-05-18
PCT/US2021/057584 WO2022094409A1 (en) 2020-11-02 2021-11-01 Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
PE20231656A1 true PE20231656A1 (es) 2023-10-17

Family

ID=81380719

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001523A PE20231656A1 (es) 2020-11-02 2021-11-01 Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos

Country Status (11)

Country Link
US (3) US20220133735A1 (cg-RX-API-DMAC10.html)
EP (1) EP4237421A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023548605A (cg-RX-API-DMAC10.html)
KR (1) KR20230129384A (cg-RX-API-DMAC10.html)
AU (1) AU2021368138A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196694A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001230A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023005056A (cg-RX-API-DMAC10.html)
PE (1) PE20231656A1 (cg-RX-API-DMAC10.html)
TW (1) TW202233613A (cg-RX-API-DMAC10.html)
WO (1) WO2022094409A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20231656A1 (es) 2020-11-02 2023-10-17 Trethera Corp Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
PT700521E (pt) 1993-05-28 2003-10-31 Baylor College Medicine Metodo e espectrometro de massa para dessorcao e ionizacao de analitos
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
JP2002502086A (ja) 1998-01-23 2002-01-22 アナリティカ オブ ブランフォード インコーポレーテッド 表面からの質量分光測定
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7259175B2 (en) 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2003072100A1 (en) 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
EP1581491A1 (en) 2003-01-06 2005-10-05 Eli Lilly And Company Indole derivatives as ppar modulators
WO2007039171A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
US8552174B2 (en) 2005-10-31 2013-10-08 Agilent Technologies, Inc. Solutions, methods, and processes for deprotection of polynucleotides
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
US8093245B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. 4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
AU2008302703B2 (en) 2007-09-19 2013-11-07 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
ES2607806T5 (es) * 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
WO2012122368A1 (en) 2011-03-08 2012-09-13 The Regents Of The University Of California Deoxycytidine kinase binding compounds
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
JP6542216B2 (ja) 2013-08-13 2019-07-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア デオキシシチジンキナーゼ阻害因子
TR201902875T4 (tr) * 2013-10-18 2019-03-21 Univ Health Network Plk-4 inhibitörünün tuz ve kristal formları.
CN105367552A (zh) * 2015-01-09 2016-03-02 苏州晶云药物科技有限公司 来那替尼马来酸盐的新晶型及其制备方法
WO2016130581A2 (en) 2015-02-09 2016-08-18 The Regents Of The University Of California Combination cancer therapy
WO2016130562A2 (en) 2015-02-09 2016-08-18 The Regents Of The University Of California Metabolic analysis of the nucleotide de novo and salvage pathways
US10570124B2 (en) * 2016-01-08 2020-02-25 The Regents Of The University Of California Deoxycytidine kinase binding compounds
US20210267885A1 (en) 2016-05-25 2021-09-02 Singapore Health Services Ptel Ltd Atropine-containing aqueous composition
KR102736865B1 (ko) * 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
WO2019165073A1 (en) * 2018-02-21 2019-08-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
PE20231656A1 (es) 2020-11-02 2023-10-17 Trethera Corp Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos

Also Published As

Publication number Publication date
US20220133735A1 (en) 2022-05-05
KR20230129384A (ko) 2023-09-08
US20250049808A1 (en) 2025-02-13
MX2023005056A (es) 2023-07-24
EP4237421A1 (en) 2023-09-06
CA3196694A1 (en) 2022-05-05
AU2021368138A1 (en) 2023-06-22
CL2023001230A1 (es) 2023-11-17
EP4237421A4 (en) 2024-11-06
TW202233613A (zh) 2022-09-01
US11446307B2 (en) 2022-09-20
JP2023548605A (ja) 2023-11-17
US20220135555A1 (en) 2022-05-05
WO2022094409A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
CO2020013601A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2022000998A1 (es) Inhibidores de las cinasas raf
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
DOP2024000081A (es) Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CO2019011708A2 (es) Compuestos inhibidores de ask1 y usos de los mismos
BR112023016590A2 (pt) Inibidores de tyk2 e seus usos
DOP2009000181A (es) Compuestos inhibidores de mek composiciones farmaceuticas que lo comprende y usos del mismo para la fabricacion de un medicamento
AR111233A1 (es) Inhibidores de tyk2, usos y métodos para la producción de los mismos
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
MX381890B (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos
MX2022002532A (es) Métodos para generar y aislar neuronas de dopamina del mesencéfalo.
CO2022018806A2 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos
CL2022001887A1 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
CO2024009144A2 (es) Inhibidores de cinasa met
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
MX2021012749A (es) Inhibidor selectivo de la jak1 cinasa.
UY38051A (es) INHIBIDORES DE LA PI4KIIIß
MX2021013010A (es) Composiciones y metodos para modular la actividad del complemento.
MX2019002615A (es) Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.